Copy Link Print Information

Mosunetuzumab

(Synonyms: BTCT-4465A; RG-7828; RO7030816)
1 Cited Publications
Avis client

Based on 1 publication(s) in Google Scholar

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 98.75%
  • CAS No.: 1905409-39-3
  • Masse moléculaire:144 kDa
  • Stockage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Experimental Validation Results for Mosunetuzumab
  • Mosunetuzumab Chemical Structure
    Mosunetuzumab Chemical Structure
CAS No.: 1905409-39-3
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Mosunetuzumab Product Recommendations:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Mosunetuzumab

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG1 kappa

  • 1/16

    Flow cytometric analysis of 1X106 Raji cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Flow cytometric analysis of 1X106 Jurkat cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • 1/16

    Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Mosunetuzumab. The EC50 for this effect is 280.4 ng/mL

  • 1/16

    Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Mosunetuzumab. The EC50 for this effect is 33.22 ng/mL.

  • Mosunetuzumab Chemical Structure
    1/16
  • Mosunetuzumab
  • Flow cytometric analysis of 1X106 Raji cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Flow cytometric analysis of 1X106 Jurkat cells with Mosunetuzumab (HY-P99033, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
  • Immobilized CD20/MS4A1 Protein-VLP, Human (HEK293, HY-P78543) can bind Mosunetuzumab. The EC50 for this effect is 280.4 ng/mL
  • Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Mosunetuzumab. The EC50 for this effect is 33.22 ng/mL.